Literature DB >> 203575

Biological properties of islets-activating protein (IAP) purified from the culture medium of Bordetella pertussis.

M Yajima, K Hosoda, Y Kanbayashi, T Nakamura, I Takahashi, M Ui.   

Abstract

The biological activities were studied of a new protein, islets-activating protein (IAP), purified from the culture medium of Bordetella pertussis. Rats injected intravenously with 1 microgram of purified IAP exhibited markedly enhanced insulin secretory responses to glucose, glucagon, epinephrine, and sulfonylureas over a period from 3 to 10 days after the injection. The degree and duration of the enhancement were proportional to the dose of IAP; the maximal effect induced by 1-2 microgram of IAP persisted for as long as 2 months. There was a highly significant correlation between the enhancement of insulin secretion and suppression of epinephrine hyperglycemia over a wide range of doses of IAP, indicating that suppression of epinephrine hyperglycemia resulted from hypoglycemic action of insulin secreted in response to epinephrine challenge. Additional actions of IAP were observed in mice; mice treated with higher doses of IAP showed symptoms were observed when lower doses of IAP were injected into mice. Thus, it is concluded that IAP is a protein primarily possessing a unique action to potentiate insulin secretory responses of experimental animals to nutritional and hormonal stimuli.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 203575     DOI: 10.1093/oxfordjournals.jbchem.a131905

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  23 in total

1.  Effects of Bordetella pertussis toxin on catecholamine inhibition of insulin release from intact and electrically permeabilized rat islets.

Authors:  S J Persaud; P M Jones; S L Howell
Journal:  Biochem J       Date:  1989-03-15       Impact factor: 3.857

2.  The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes.

Authors:  C M Heyworth; A M Grey; S R Wilson; E Hanski; M D Houslay
Journal:  Biochem J       Date:  1986-04-01       Impact factor: 3.857

3.  Bordetella pertussis does not induce beta-adrenergic blockade.

Authors:  E Hewlett; A Spiegel; J Wolff; G Aurbach; C R Manclark
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

4.  Epitopes on the S1 subunit of pertussis toxin recognized by monoclonal antibodies.

Authors:  K J Kim; W N Burnette; R D Sublett; C R Manclark; J G Kenimer
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

5.  Effect of protein kinase C inhibitor (H-7) and calmodulin antagonist (W-7) on pertussis toxin-induced IL-1 production by human adherent monocytes. Comparison with lipopolysaccharide as a stimulator of IL-1 production.

Authors:  H Taniguchi; T Sakano; T Hamasaki; H Kashiwa; K Ueda
Journal:  Immunology       Date:  1989-06       Impact factor: 7.397

6.  Islet-activating protein blocks glucagon desensitization in intact hepatocytes.

Authors:  C M Heyworth; E Hanski; M D Houslay
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

7.  Interaction of monoclonal antibodies with pertussis toxin and its subunits.

Authors:  D W Frank; C D Parker
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

Review 8.  Toward a mechanism-based in vitro safety test for pertussis toxin.

Authors:  Stefan F C Vaessen; Martijn W P Bruysters; Rob J Vandebriel; Saertje Verkoeijen; Rogier Bos; Cyrille A M Krul; Arnoud M Akkermans
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

9.  Effect of islet activating protein on glucose tolerance, insulin secretion and insulin responsiveness in the NZO mouse.

Authors:  C A Re; M C Veroni; R G Larkins
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

10.  In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor.

Authors:  B D Meade; P D Kind; J B Ewell; P P McGrath; C R Manclark
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.